Australia markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.10-0.57 (-1.20%)
At close: 4:00PM EDT
47.80 +0.70 (1.49%)
Pre-market: 07:17AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close47.67
Open47.51
Bid45.93 x 800
Ask51.50 x 1000
Day's range46.08 - 48.57
52-week range25.31 - 141.01
Volume638,385
Avg. volume707,688
Market cap6.199B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
    GlobeNewswire

    GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

    – Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease – – U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab – – Further research initiated to evaluate intramuscular administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk patients in a Ph

  • Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
    GlobeNewswire

    Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021

    – Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET –SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress taking place virtually from June 23-26, 2021. Vir will hold a conference c

  • Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
    GlobeNewswire

    Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

    SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:00 pm PT / 3:00 pm ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presen